INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);UNIVERSITE PAUL SABATIER TOULOUSE III;AFFICHEM
发明人:
Sandrine SILVENTE POIROT,Marc POIROT,Julie LEIGNADIER,Philippe DE MEDINA,Michel RECORD
申请号：
US16335538
公开号：
US20200016177A1
申请日:
2017.09.22
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to methods and pharmaceutical compositions for reprogramming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secretion and the production of modified exosomes with anti-tumor properties (DDA-exosomes) via a mechanism dependent of the expression of the LXRbeta in the parental cells. In particular, one object of the present invention relates to a method of promoting Th1 differentiation and functionality and CD8+ cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA or DDA-exosomes.
